115 filings
ARS
2023 FY
SWTX
SpringWorks Therapeutics Inc
5 Apr 24
Annual report to shareholders
4:13pm
DEFA14A
SWTX
SpringWorks Therapeutics Inc
5 Apr 24
Additional proxy soliciting materials
4:09pm
DEF 14A
SWTX
SpringWorks Therapeutics Inc
Definitive proxy
5 Apr 24
4:05pm
8-K
SWTX
SpringWorks Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
8:28am
424B5
SWTX
SpringWorks Therapeutics Inc
27 Feb 24
Prospectus supplement for primary offering
8:23am
S-8
1e6rjyts75n95 cfm
27 Feb 24
Registration of securities for employees
7:29am
8-K
5h9y8rilo2rgmzegyu
27 Feb 24
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
6:44am
8-K
b3rhcc9n1
2 Feb 24
Departure of Directors or Certain Officers
4:01pm
8-K
6uh8z7yr
6 Dec 23
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
4:10pm
424B5
84jiswjdk5
6 Dec 23
Prospectus supplement for primary offering
4:05pm
424B5
i2c0wsv75t5oqt
4 Dec 23
Prospectus supplement for primary offering
4:19pm
8-K
tx9vis
28 Nov 23
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
9:00am
8-K
vmg6aj
17 Nov 23
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
7:00am
UPLOAD
dfxxjxjcv
14 Nov 23
Letter from SEC
12:00am
CORRESP
5oo2in5jz x549xfmv3
8 Nov 23
Correspondence with SEC
12:00am
S-3ASR
lch 5zm23
2 Nov 23
Automatic shelf registration
7:54am
8-K
n73oh4nxciee82
2 Nov 23
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
6:35am
UPLOAD
akf ajsbn
13 Oct 23
Letter from SEC
12:00am